The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

After raising $292 million in its Hong Kong IPO, AI discovery and development biotech, Insilico Medicine, signed an R&D collaboration with French pharma Servier SA valued at $888 million to discover ...

The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...